Interferon-beta1 ( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	2

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04079088 (ClinicalTrials.gov)	June 30, 2021	3/9/2019	Study to Evaluate Oral BIIB061 Added to Interferon-beta1(IFN-ß1) or Glatiramer Acetate in Relapsing ...	A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Phase 2 Study to Evalu ...	Relapsing Multiple Sclerosis	Drug: Placebo;Drug: BIIB061;Biological: Interferon-beta1;Drug: Glatiramer acetate	Biogen	NULL	Not yet recruiting	18 Years	55 Years	All	300	Phase 2	NULL
2	NCT00219908 (ClinicalTrials.gov)	July 1999	16/9/2005	Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis	Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis: ...	Relapsing-Remitting Multiple Sclerosis	Drug: Mitoxantrone	Rennes University Hospital	Bayer;Wyeth is now a wholly owned subsidiary of Pfizer;Farmades, Italy	Terminated	18 Years	45 Years	Both	124	Phase 2	France;Italy

First Previous1Next Last